The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study)
Leonardo Clavijo, Jorge Caro, Jongkyu Choi, Jorge A. Caro, Han W. Tun, Vincent L. Rowe, S. Ram Kumar, David M. Shavelle, Ray Matthews
Topics & Concepts
MedicineEvolocumabClaudicationIntermittent claudicationPlaceboCardiologyInternal medicinePeripheralArterial diseaseVascular diseaseCholesterolApolipoprotein BPathologyApolipoprotein A1Alternative medicinePeripheral Artery Disease ManagementRheumatoid Arthritis Research and TherapiesSystemic Sclerosis and Related Diseases